

Amendments to the Claims

Claims 1-3 (Cancelled)

Claim 4 (Previously presented): The pharmaceutical composition of claim 5 wherein the organic phenolic compound is selected from isopropyl-o-cresol, isopropyl-cresol and combinations thereof.

Claim 5 (Previously presented): A pharmaceutical composition for treating an infection in an animal comprising:

- (a) at least one antimicrobial compound comprising an organic phenolic compound reacted with at least one Group I hydroxide base; and
- (b) a pharmaceutically acceptable carrier for parenteral administration.

Claim 6 (Previously presented): The pharmaceutical composition of claim 5 wherein the Group I hydroxide base is selected from sodium hydroxide, potassium hydroxide and combinations thereof.

Claim 7 (Previously presented): A pharmaceutical composition comprising:

- (a) at least one antimicrobial compound comprising isopropyl-o-cresol and isopropyl-cresol chemically reacted with sodium hydroxide and potassium hydroxide; and
- (b) a pharmaceutically acceptable carrier for parenteral administration.

Claim 8 (Previously presented): The pharmaceutical composition of claim 5 comprising from 0.1% by weight of the pharmaceutical composition to 15% by weight of the pharmaceutical composition of antimicrobial compound.

Claim 9 (Previously presented): The pharmaceutical composition of claim 8 wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.

Claim 10 (Previously presented): The pharmaceutical composition of claim 5 comprising from 3.5% by weight of the pharmaceutical composition to 10% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.

Claim 11 (Original): The pharmaceutical composition of claim 10 wherein the pharmaceutically acceptable carrier comprises olive oil.

Claim 12 (Previously presented): The pharmaceutical composition of claim 5 comprising from 0.1% by weight of the pharmaceutical composition to 1.0% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

Claim 13 (Currently amended): The pharmaceutical composition of claim 12 comprising an antimicrobial compound in an amount of from 0.5% by weight of the pharmaceutical composition to 0.8% by weight of the pharmaceutical composition of antimicrobial compound, and wherein the pharmaceutically acceptable carrier comprises sodium chloride in an amount of from 0.5% by weight of the pharmaceutically acceptable carrier to 1.0% by weight of the pharmaceutically acceptable carrier of sodium chloride pharmaceutical composition.

Claim 14 (Previously presented): A pharmaceutical composition comprising:

- (a) at least one antimicrobial compound, comprising isopropyl-o-cresol and isopropyl cresol wherein there is more isopropyl-o-cresol than isopropyl cresol reacted with at least one Group I salt; and
- (b) a pharmaceutically acceptable carrier for parenteral administration.

Claim 15 (Previously presented): A pharmaceutical composition comprising:

- (a) between 55% by weight and 99% by weight of an antimicrobial compound comprising isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1% by weight and 45% by weight of an antimicrobial compound comprising of isopropyl cresol or base reacted isopropyl cresol.

Claim 16 (Previously presented): The pharmaceutical composition of claim 15 wherein the composition comprises:

- (a) between 75% by weight and 99% by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1% by weight and 25% by weight of isopropyl cresol or base reacted isopropyl cresol.

Claim 17 (Previously presented): The pharmaceutical composition of claim 15 wherein the composition antimicrobial compound comprises

- (a) between 90% by weight and 99% by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1% by weight and 10% by weight of isopropyl cresol or base reacted isopropyl cresol.

Claim 18 (Previously presented): The pharmaceutical composition of claim 15 wherein the composition comprises:

- (a) between 95% by weight and 99% by weight of isopropyl-o-cresol or base reacted isopropyl-o-cresol; and
- (b) between 1% by weight and 5% by weight of isopropyl cresol or base reacted isopropyl cresol.

Claim 19 (Previously presented): The pharmaceutical composition of claim 5 wherein the animal is selected from humans, horses, cows, pigs, sheep, goats, rabbits, dogs, cats, chickens, turkeys, ducks and birds.

Claim 20 (Previously presented): The pharmaceutical composition of claim 15 wherein the infection comprises infection by *E. coli*, *Salmonella* spp., *Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Cornebacterium* spp., *Bacillus* spp., *Clostridium* spp., *Spherophorus* spp., *Candida* spp., *Trychophyton* spp., *Microsporum* spp., *Micobacterium* spp., *Cryptosporidia* spp., *Microsporidia* spp., *Listeria monocytogenes*, *Lawsonia intracellularis*, *Treponema desynteriae*, *Enterococcus* spp., *Heamophylus* spp., *Campylobacter* spp., *Chlamydia*, *Brucella* spp., or *Vibrio* spp.

Claims 21-36 (Cancelled)

Claim 37 (Previously presented): The pharmaceutical composition of claim 7, comprising from 0.1% by weight of the pharmaceutical composition to 15% by weight of the pharmaceutical composition of antimicrobial compound.

Claim 38 (Previously presented): The pharmaceutical composition of claim 37, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.

Claim 39 (Previously presented): The pharmaceutical composition of claim 7, comprising from 3.5% by weight of the pharmaceutical composition to 10% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.

Claim 40 (Previously presented): The pharmaceutical composition of claim 39, wherein the pharmaceutically acceptable carrier comprises olive oil.

Claim 41 (Previously presented): The pharmaceutical composition of claim 7 comprising from 0.1% by weight of the pharmaceutical composition to 1.0% by weight of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

Claim 42 (Currently amended): The pharmaceutical composition of claim 7 comprising an antimicrobial compound in an amount of from 0.5% by weight of the pharmaceutical composition to 0.8% by weight of the pharmaceutical composition of antimicrobial compound, and wherein the pharmaceutically acceptable carrier comprises sodium chloride in an amount of from 0.5% by weight of the pharmaceutically acceptable carrier to 1.0% by weight of the pharmaceutically acceptable carrier of sodium chloride pharmaceutical composition.

Claim 43 (Previously presented): The pharmaceutical composition of claim 12 wherein the infection comprises infection by *E. coli*, *Salmonella* spp., *Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Corinebacterium* spp., *Bacillus* spp., *Clostridium* spp., *Spherophorus* spp.,

Candida spp., *Trychophyton* spp., *Microsporum* spp., *Micobacterium* spp., *Cryptosporidia* spp., *Microsporidia* spp., *Listeria monocytogenes*, *Lawsonia intracellularis*, *Treponema desynteriae*, *Enterococcus* spp., *Heamophilus* spp., *Campylobacter* spp., *Chlamydia*, *Brucella* spp., or *Vibrio* spp.

Claim 44 (New): A pharmaceutical composition for treating mastitis in a cow comprising: 47.5% sodium isopropyl-o-cresol; 47.5% potassium isopropyl-o-cresol; 2.5% sodium isopropyl-cresol; and 2.5% potassium isopropyl-cresol.

Claim 45 (New): A pharmaceutical composition for treating tendon inflammation in horses comprising: 47.5% sodium isopropyl-o-cresol; 47.5% potassium isopropyl-o-cresol; 2.5% sodium isopropyl-cresol; and 2.5% potassium isopropyl-cresol.